The Night and Day cold and flu system is commonly used for providing coordinated symptomatic relief across multiple domains of discomfort associated with acute viral upper respiratory infections, such as the common cold and influenza. The system is commonly used to provide symptomatic relief that supports patients during episodes of heightened discomfort.

The medication is applied in addressing symptoms that interfere with daily comfort in the upper airways and systemically. It is commonly used to help with alleviating disruptive manifestations including headache, fever, body aches, nasal congestion, runny nose, and sneezing. A therapeutic benefit is its use in managing symptoms across the full day-night cycle. The nighttime component provides specific relief from persistent cold symptoms that interfere with sleep, thereby supporting the patient's ability to rest and assisting with managing symptoms that may interfere with functional stability during difficult episodes.

Quick Fact: Relief for Acute Symptomatic Episodes

The formulation supports patients during difficult episodes by easing distress associated with systemic discomfort, upper airway congestion, and sleep disruption caused by common cold and flu symptoms.

Regulatory References

1. NIH DailyMed drug label for combination cold/flu relief

Official Eligibility for Night and Day Cold System

The eligibility for the Night and Day combination medicine is strictly defined by regulatory authorities based on age, concurrent medications, and pre-existing conditions.

Populations Permitted Under Standard Labeled Conditions

Use is established for adults and children 12 years of age and older.

Absolute Contraindications (Must Not Use)

The medicine is formally contraindicated in several groups, as explicitly stated in regulatory labeling. Individuals must not use this product if they are currently taking a Monoamine Oxidase Inhibitor (MAOI), or have stopped taking one within the last 14 days. Use is also prohibited for patients with a known allergy or hypersensitivity to Acetaminophen, Diphenhydramine, or any other ingredients. The product must not be used by children under 12 years of age or by any person taking other medicines containing Acetaminophen or Diphenhydramine.

Restricted Use and Conditional Eligibility

Specific populations are advised to ask a health professional before use. These include individuals with high blood pressure, heart disease, diabetes, glaucoma, or thyroid disease. Patients with liver disease or breathing problems like chronic bronchitis also fall under this restricted status. Furthermore, individuals who are pregnant or breastfeeding must consult a health professional before using this medicine.

Interactions with Other Medicines and Products

This section describes formally documented interaction patterns and administration restrictions as stated in government regulatory labeling for the combination product (Acetaminophen, Diphenhydramine, and Phenylephrine/Phenylpropanolamine).

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a strictly contraindicated combination. Regulatory documents require that the combination product not be used concurrently or within 14 days of discontinuing MAOI therapy to allow for appropriate clearance. Use of the product with any other medicine containing Acetaminophen is also prohibited to prevent accidental cumulative overdose, a restriction mandated to avoid the risk of severe hepatotoxicity.

Pharmacodynamic and Substance Interactions

The label documents that co-administration with other Central Nervous System (CNS) Depressants (e.g., sedatives, opioids) may result in additive CNS depression, increasing the risk of drowsiness due to the Diphenhydramine component. Similarly, combining the product with other sympathomimetic agents may lead to additive adrenergic effects.

Alcohol consumption is officially documented as a substance interaction that increases the risk of Acetaminophen-related liver damage. This risk is specifically noted as amplified for individuals who are chronic alcohol users (three or more drinks per day).

Central Modulation of Temperature and Pain Signaling

The mechanism of action involves the inhibition of Cyclooxygenase (COX) enzymes, primarily affecting the synthesis of Prostaglandin E2 ( PGE2) within the Central Nervous System (CNS), particularly in the hypothalamic region. This molecular action modulates the signaling that dictates the body's internal temperature set point. This facilitates the activation of physiological processes for systemic heat transfer and contributes to the modulation of nociceptive signaling through central pathways.

Dual Receptor Antagonism for Secretion Control and CNS Suppression

The nighttime component engages in competitive antagonism at both H1 Histamine and Muscarinic Acetylcholine receptors throughout the body and the CNS. This dual blockade interrupts signaling that drives vascular leakage and secretion, producing an anti-secretory physiological effect. The H1 antagonism in the brain concurrently suppresses the histaminergic arousal pathway, leading to the physiological consequence of central somnolence.

Localized Vascular Contraction via alpha1-Adrenergic Agonism

The mechanism relies on the direct agonism of alpha1-Adrenergic receptors located on the blood vessels in the nasal mucosa. This interaction triggers the contraction of vascular smooth muscle, which reduces blood volume and fluid extravasation in the sinusoids. This cascade results in the reduction of tissue volume in the affected mucous membranes, which is the functional consequence of the localized vasoconstriction.

How to Use Night and Day

The Night and Day system is administered via the oral route as a coordinated, two-part regimen for the short-term management of cold and flu symptoms. This usage pattern is structured to ensure appropriate component delivery during waking and sleeping hours.

---

Standard Administration and Dosing

The medicine is taken as an as-needed (PRN) administration, with a strictly defined frequency and maximum daily limit. The dose is standardized for adults and children 12 years of age and older.

Usage Entity	Official Administration Guidelines
Route of Administration	Oral, using solid dose units (caplets, tablets) or liquid solution.
Dosing Schedule	Standard dose is typically two caplets or the corresponding liquid volume per interval. The total daily intake of Acetaminophen from all sources must not exceed 4000 mg.
Frequency	Dosing is restricted to a period of every 4 to 6 hours as needed, and the total intake must not exceed the maximum number of doses in a 24-hour period (typically four to six doses).
Duration Constraint	Use must be limited to no more than seven days for cold symptoms, unless otherwise directed by a healthcare professional.

---

Procedural Context and Constraints

Administration involves taking the dose with water, and specific constraints apply to prevent excessive intake of active ingredients. Users must not combine this product with any other medication containing Acetaminophen or any other drug containing the sedating antihistamine Diphenhydramine. For pediatric use, the product is contraindicated for children under 6 years of age, while specific reduced dosing may apply for children aged 6 to under 12 years for certain daytime formulations.

Research Evidence / Overview of Studies for Night and Day

This entire section is designed to give you a transparent overview of the research that has explored Night and Day so far. This information describes what researchers studied and what findings they reported; it is not clinical advice and should not be used to predict your personal outcome.

---

Evidence for use in Chronic Pain Management (Non-Cancer)

Research has explored Night and Day in the context of conditions characterized by fluctuating or episodic manifestations of chronic pain that is not related to cancer. Research included a limited number of randomized controlled trials (RCTs), many of which were short-term, as well as some observational studies. These studies primarily focused on measuring outcomes related to physical discomfort and outcomes reflecting daily functioning.

Studies reported measurements indicating changes in patient-reported outcomes describing perceived discomfort. Findings describe group patterns observed in the studies, though evidence remains limited and heterogeneous. Long-term effects are not fully established, and certainty remains low regarding sustained changes.

---

Evidence for use in Neuropathic Pain

Research has explored Night and Day in the context of studies examining symptom intensity or variability in conditions involving periods of heightened symptoms, specifically neuropathic pain. Studies monitored short-term symptom changes in conditions such as diabetic peripheral neuropathy. Research primarily focused on changes in pain intensity over defined, short time intervals.

Studies report measurements observed during the study period. However, the outcomes reported were generally short-term, and results apply only to the specific populations studied. There is limited information for long-term outcomes, as follow-up durations were restricted.

---

Long-term Studies and Follow-up

Research so far indicates that studies for Night and Day have typically focused on short-term symptom patterns. There is limited information for long-term outcomes, as follow-up durations were restricted in the available trials. Long-term effects are not fully established, and future research is needed to monitor patterns of change over extended periods.

---

What is Still Uncertain About Night and Day

Evidence highlights what is known—and what is still uncertain. Sample sizes were modest across many of the available trials. The overall evidence quality varies across studies, and findings were mixed in some areas, meaning we cannot conclude uniform patterns. Research provides context but not individual predictions.

Common questions about Night and Day (FAQ)

Q: Can Night and Day be taken on an empty stomach, according to the official label?

The official instructions for taking Night and Day typically clarify how the medication should be administered. They specify taking the dose with water and may state whether consumption is recommended with food or on an empty stomach, or if it makes no difference to the absorption.

Q: Is it necessary to finish the entire course of Night and Day, even if symptoms improve?

Regulatory labeling indicates that Night and Day is intended only for the short-term management of cold symptoms. The official duration constraint specifies that the product should typically be limited to no more than seven days of use.

Q: Are there known drug interactions with common herbal supplements and Night and Day?

Official documents describe known interactions with major drug classes, including CNS depressants and sympathomimetic agents. Regulatory warnings about these drug classes exist because certain herbal products may contain components that act similarly, which could potentially lead to an interaction.

Q: How quickly do the effects of Night and Day typically wear off?

Regulatory administration guidelines recommend taking a dose of Night and Day every 4 to 6 hours as needed. This time frame is generally reflective of the expected duration for the therapeutic effects of the medicine.

Q: Is it possible to use Night and Day while operating heavy machinery?

Official product information contains a specific warning about the use of Night and Day when engaging in tasks requiring full attention. Due to the sedating antihistamine in the nighttime component, there is a potential for drowsiness and impaired mental or physical abilities, including those needed for operating machinery or driving.

Q: Why might the label include precautions for people with certain pre-existing conditions?

Regulatory documents include warnings and precautions to alert users to known physiological risks associated with the drug's components. These precautions specifically detail certain pre-existing conditions, such as high blood pressure or heart disease, where components like phenylephrine may require caution or be contraindicated.

Q: What is the difference between Night and Day and a placebo in research studies?

In clinical trials, a placebo is described as an inactive substance that looks identical to the actual drug. Researchers use it as a control comparison to measure the difference between the health outcomes of participants receiving Night and Day versus those receiving no active ingredient, which helps establish the drug's effect.

Q: Is the main benefit of Night and Day immediate or does it build up over time?

Official regulatory documents describe Night and Day as a medication intended for the 'as-needed' relief of symptoms. This 'PRN' classification means the product is typically used for symptoms that require relief shortly after administration, rather than needing to build up in the body over an extended period.

Q: What are the most common reasons a medical professional might advise against using Night and Day?

Regulatory documents identify strict contraindications and known drug or substance interactions that restrict the use of the drug. These restrictions are based on specific risks and include combining the product with MAOIs (Monoamine Oxidase Inhibitors) or consuming large amounts of alcohol while taking the Acetaminophen component.

Q: Is Night and Day a brand name or a generic medicine?

Official regulatory records identify the product's classification, including its name and active ingredients. This information establishes whether the product is registered as a proprietary (brand) combination or a nonproprietary (generic) combination of its components.

Q: What are the most commonly reported side effects of Night and Day?

Official product information lists the observed side effects based on reports from clinical trials and post-marketing surveillance. These regulatory documents categorize the effects by frequency, such as common or very common, to provide an overview of what was generally reported by participants.

Q: How long does Night and Day stay in the body after the last dose?

Official pharmacokinetic data describes the half-life (t1/2) of the active components, which is the time needed for the amount of medicine in the body to decrease by half. This regulatory information provides a factual measure of how long the ingredients may take to be substantially cleared from the system.

Q: What are the known severe or rare side effects of Night and Day?

Regulatory labels explicitly list all adverse reactions observed, which include those classified as rare or severe. For example, these documents often contain warnings about the potential for signs of liver damage due to the Acetaminophen component or the risk of serious allergic reactions.

Q: Is Night and Day ever associated with dependency or withdrawal symptoms?

Regulatory documents include a section that classifies the drug's potential for abuse and dependence. This section states whether any of the components are scheduled substances and whether official reports indicate an association with withdrawal symptoms.

Q: Can Night and Day be used with oral birth control pills?

Official drug interaction documents list all known substances and medications that have a documented clinical interaction with Night and Day. If oral birth control pills are not specifically mentioned, it typically suggests that no significant interaction has been officially documented for the active components.

Q: What is the official information regarding Night and Day and use during breastfeeding?

Official regulatory information for Night and Day includes specific statements regarding the use of the product during breastfeeding. These documents detail whether the drug's components are known to transfer into human milk and any known risks to the nursing child.

Q: Do people with kidney problems need special considerations when using Night and Day?

Regulatory guidelines include specific administration recommendations for individuals with impaired kidney function. Official documents address whether this population requires a modified dose or special considerations when using the medicine.

Q: Does taking Night and Day affect the results of common lab tests?

Regulatory documents list known instances where the drug's components may interfere with the accuracy of certain blood or urine laboratory test results.

Q: What is a Boxed Warning, and does Night and Day have one?

A Boxed Warning, sometimes called a Black Box Warning, is the strongest type of alert required by the FDA to call attention to serious safety concerns. Regulatory labels for Night and Day explicitly state whether the product contains a Boxed Warning and detail the specific safety information covered by this warning.

Q: Does official documentation say Night and Day tablets can be split or crushed?

Official regulatory documentation includes instructions regarding the administration and physical form of the medicine. These documents clarify if the tablet must be swallowed whole to maintain its integrity and intended therapeutic release profile, or if there is information about splitting or crushing.

Q: How should Night and Day be stored, according to its official labeling?

Official regulatory documents provide explicit instructions detailing the required storage conditions for Night and Day. These guidelines cover factors such as the necessary storage temperature and whether the product should be kept in its original container and protected from moisture.

Q: Does Night and Day contain common allergens like lactose or gluten?

Official regulatory labels contain a complete list of all inactive ingredients, known as excipients, used in the product. This comprehensive list allows individuals to check for the presence of common allergens, such as lactose, gluten, or certain coloring agents.

Q: Is Night and Day known to interact with caffeine consumption?

Regulatory documents list all known substance interactions. This list includes information about whether the central nervous system (CNS) stimulating component or the Acetaminophen component is significantly affected by caffeine consumption.

Q: Does the Night and Day label describe any potential for vision changes?

Regulatory lists of adverse reactions explicitly detail whether vision changes have been reported. Specific effects like blurred vision are often associated with the sedating Diphenhydramine component of the medicine.

Q: Can Night and Day be taken with common acid-reducing medicines?

Official regulatory documents list known drug interactions with Night and Day. If common acid-reducing medicines are not specifically listed in the interaction section, it typically suggests that no officially documented significant clinical interaction exists for concurrent use.

Q: Are there specific monitoring requirements mentioned for patients using Night and Day?

Official product documentation details specific warnings and precautions for use. If applicable, this section outlines any specific clinical monitoring requirements, such as checking blood pressure or liver function tests, that may be necessary during the use of Night and Day.

Q: Does Night and Day have a known interaction with grapefruit juice?

Regulatory labels explicitly state if the product interacts with specific food substances, such as grapefruit juice. This interaction is usually detailed if any of the drug's active components are known to be metabolized by the specific enzyme systems that grapefruit juice affects.

Q: Can Night and Day affect blood sugar levels?

Official regulatory lists of adverse reactions explicitly state whether there are reported changes in blood sugar levels or glucose metabolism associated with the use of Night and Day. This information is available in the section detailing undesirable effects.

Q: How does the body eliminate Night and Day after it has been metabolized?

Official pharmacokinetic documents describe the process by which the body clears the active components of the drug. This regulatory information details the primary route of elimination, specifying which organ systems, such as the kidneys or liver, are responsible for the clearance of the medicine after it has been metabolized.

The storage and disposal of the Night and Day combination product must comply with official regulatory labeling to ensure stability and public safety.

Storage Requirements

The product must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, which must be tightly closed, and protected from excessive moisture and freezing. All dosage forms must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must be disposed of according to local regulations for pharmaceutical waste. Unless the label instructs otherwise, the product must not be flushed down the toilet or poured into a drain. Disposal should follow established guidelines, such as utilizing drug take-back programs or mixing with an unappealing substance, sealing in a bag, and discarding in household trash.